SVRA Savara Inc

USD 4.45 0.21 4.95283
Icon

Savara Inc (SVRA) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 4.45

+0.21 (+4.95)%

USD 0.66B

1.25M

USD 9.25(+107.87%)

N/A

Icon

SVRA

Savara Inc (USD)
COMMON STOCK | NSD
USD 4.45
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.66B

N/A

USD 4.45

Savara Inc (SVRA) Stock Forecast

Show ratings and price targets of :
USD 9.25
(+107.87%)

Based on the Savara Inc stock forecast from 4 analysts, the average analyst target price for Savara Inc is USD 9.25 over the next 12 months. Savara Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Savara Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Savara Inc’s stock price was USD 4.45. Savara Inc’s stock price has changed by -7.10% over the past week, -7.68% over the past month and +148.60% over the last year.

No recent analyst target price found for Savara Inc
No recent average analyst rating found for Savara Inc

Company Overview Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune ...Read More

1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047

37

December

USD

USA

Adjusted Closing Price for Savara Inc (SVRA)

Loading...

Unadjusted Closing Price for Savara Inc (SVRA)

Loading...

Share Trading Volume for Savara Inc Shares

Loading...

Compare Performance of Savara Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for SVRA

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Savara Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -3.06 (-0.76%) USD107.38B 29.93 21.06

ETFs Containing SVRA

Symbol Name SVRA's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Savara Inc (SVRA) Stock

Based on ratings from 4 analysts Savara Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.

Unfortunately we do not have enough data on SVRA's stock to indicate if its a good dividend stock.

Based on targets from 4 analysts, the average taret price for SVRA is USD 9.25 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 6.

Unfortunately we do not have enough data on SVRA's stock to indicate if its overvalued.

The last closing price of SVRA's stock was USD 4.45.

The most recent market capitalization for SVRA is USD 0.66B.

Based on targets from 4 analysts, the average taret price for SVRA is projected at USD 9.25 over the next 12 months. This means that SVRA's stock price may go up by +107.87% over the next 12 months.

We can't find any ETFs which contains Savara Inc's stock.

As per our most recent records Savara Inc has 37 Employees.

Savara Inc's registered address is 1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047. You can get more information about it from Savara Inc's website at https://www.savarapharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...